Research has shown that the combination of dabrafenib and trametinib demonstrates meaningful efficacy in various BRAF-positive tumor types, such as NSCLC, melanoma, and ATC, and among patients with some rare cancers that lack other treatment options. This evidence concerns the gene BRAF and melanoma.